ArticleMethods in molecular biology (Clifton, N.J.)2026
Gangliosides and Membrane Microdomains.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monosialoganglioside GM3 is the simplest ganglioside involved in various cellular signaling via plasma membrane. Elucidating the precise distribution of GM3 helps to understand its function. Although several anti-GM3 monoclonal antibodies are established, the results from the immunostaining of the antibody on the cell surface need to be carefully evaluated: the antibody binds to GM3 in sparse but not in confluent cells, and the binding is temperature dependent. Our model membrane study evidenced that GM3 makes clusters in the less fluid membrane environment, where monoclonal anti-GM3 antibodies showed stronger binding. These results suggest that anti-GM3 antibody senses GM3 clustering and the number and/or size of GM3 clusters differ in different membrane environments. This chapter describes the detailed protocols to examine the binding of anti-GM3 antibodies to different lipid mixtures by solid phase reaction, as well as to high- and low-density melanoma cells. This chapter also describes the methods to study the clustering of fluorescent GM3 analogs in different lipid compositions at various temperatures.
Indexed as
Identifiers
42613535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.